ClearPoint Neuro price target raised to $25 from $19 at Stifel

Stifel analyst Mathew Blackman raised the firm’s price target on ClearPoint Neuro (CLPT) to $25 from $19 and keeps a Buy rating on the shares. The analyst calls ClearPoint “one of the more “under-the-radar” — yet increasingly compelling — stories we cover,” citing the company’s unique business model that blends traditional MedTech with a rapidly expanding Biologics and Drug Delivery franchise.